Between 2001 and 2006 18 research sites of 22 global pharmaceutical companies were closed in Europe (only 2 were opened) while in the same period these companies opened 14 research sites in Asia (one was closed) and six in the U.S (five were shut down).

Member States shall not take into account voting rights or shares which investment firms or credit institutions may hold as a result of providing the underwriting of financial instruments and/or placing of financial instruments on a firm commitment basis included under point 6 of Section A of Annex I to Directive 2004/39/EC , provided that those rights are, on the one hand, not exercised or otherwise used to intervene in the management of the issuer and, on the other, disposed of within one year of acquisition.

Pursuant to Directive 91/67/EEC, a Member State may submit to the Commission a programme designed to enable it subsequently to initiate the procedures for a zone, or a farm situated in a non-approved zone, to obtain the status of approved zone, or of approved farm situated in a non-approved zone, as regards one or more of the fish diseases viral haemorrhagic septicaemia (VHS) and infectious haematopoietic necrosis (IHN).

Core obstacles to the exchange of information between law enforcement authorities can only be effectively addressed on the basis of a firm commitment of Member States to take concrete measures towards the setting up of a European Criminal Intelligence Model (see paragraph 2.3).

Core obstacles to the exchange of information between law enforcement authorities can only be effectively addressed on the basis of a firm commitment of Member States to take concrete measures towards the setting up of a European Criminal Intelligence Model (see paragraph 2.3).

In determining whether the criteria for a qualifying holding referred to in this Article are fulfilled, Member States shall not take into account voting rights or shares which investment firms or credit institutions may hold as a result of providing the underwriting of financial instruments and/or placing of financial instruments on a firm commitment basis included under point 6 of Section A of Annex I, provided that those rights are, on the one hand, not exercised or otherwise used to intervene in the management of the issuer and, on the other, disposed of within one year of acquisition.